Adenosine receptors as therapeutic targets
Open accessThe DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, A1 and A2A receptors are considered the principal targets mediating caffeine’s physiological effects.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“A key mechanism underlying the interaction between caffeine and exercise is caffeine’s pharmacological action as a competitive adenosine receptor antagonist.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Instead, competitive blockade of A1 and A2A adenosine receptors is widely regarded as the central mechanism underlying caffeine’s physiological effects during both habitual intake and exercise (Figure 1) [28,29,30,31].”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Within the range of plasma concentrations relevant to sports nutrition practice, typically micromolar levels achieved after low-to-moderate caffeine intake, caffeine’s primary mechanism of action is unlikely to involve phosphodiesterase (PDE) inhibition or direct intracellular Ca2+ release.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“This effect modulates key physiological processes such as anti-inflammatory responses, angiogenesis, and vasodilation, as illustrated in Figure 2 (left panel) [52,66,67,68].”
From Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives (2025) · cites this paper as [68]
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Self-citationCalker, D. V., Müller, M., & Hamprecht, B. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb05236.x · Cited by 1,371
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Astrocytic Purinergic Signaling Coordinates Synaptic Networks
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J.-Y., Takano, H., Moss, S. J., McCarthy, K., & Haydon, P. G. (2005) · Science · doi:10.1126/science.1116916 · Cited by 1,280
Adenosine: A Mediator of the Sleep-Inducing Effects of Prolonged Wakefulness
Porkka-Heiskanen, T., Strecker, R. E., Thakkar, M., Bjørkum, A. A., Greene, R. W., & McCarley, R. W. (1997) · Science · doi:10.1126/science.276.5316.1265 · Cited by 1,252
Subclasses of external adenosine receptors.
Londos, C., Cooper, D. M., & Wolff, J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.5.2551 · Cited by 1,081
Extracellular metabolism of ATP and other nucleotides
Zimmermann, H. (2000) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100000309 · Cited by 990
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
Ledent, C., Vaugeois, J.-M., Schiffmann, S. N., Pedrazzini, T., Yacoubi, M. E., Vanderhaeghen, J.-J., Costentin, J., Heath, J. K., Vassart, G., & Parmentier, M. (1997) · Nature · doi:10.1038/41771 · Cited by 918
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 899
Research works printed but not linked: 1
- Ji, X. D. & Jacobson, K. A. [3H]-ZM241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des. Discov. 16, 217–226 (1999).
Cited by
Items 301–400 of 1,001
Perspective Design of Chalcones for the Management of CNS Disorders: A Mini-Review
Mathew, B., Parambi, D. G. T., Sivasankarapillai, V. S., Uddin, M. S., Suresh, J., Mathew, G. E., Joy, M., Marathakam, A., & Gupta, S. V. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666190610111246 · Cited by 55
Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics?
Dubrovina, I., Miškinis, K., Lyepshina, S., Yan-n, Y., Hoffmann, H., Zaleskis, R., Nunn, P., & Zignol, M. (2008) · PubMed · Cited by 62
Keep an eye on adenosine: Its role in retinal inflammation
Santiago, A. R., Madeira, M. H., Boia, R., Aires, I. D., Rodrigues‐Neves, A. C., Santos, P. F., & Ambrósio, A. F. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107513 · Cited by 62
Dulla, C. G., Frenguelli, B. G., Staley, K. J., & Masino, S. A. (2009) · Journal of Neurophysiology · doi:10.1152/jn.90695.2008 · Cited by 52
Bone targeting nanocarrier-assisted delivery of adenosine to combat osteoporotic bone loss
Hoque, J., Shih, Y.-R. V., Zeng, Y., Newman, H., Sangaj, N. S., Arjunji, N., & Varghese, S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120819 · Cited by 58
Drug discovery inspired by bioactive small molecules from nature
Kim, S., Lim, S.-W., & Choi, J. (2022) · Animal Cells and Systems · doi:10.1080/19768354.2022.2157480 · Cited by 61
“…for cellular responses such as cell growth, differentiation, immunity, neuronal activation, and morphological changes by directly binding and stimulating their cognate cellular receptors (Schreiber 2005; Jacobson and Gao 2006; Traynelis et al. 2010; Blaho and Hla 2014; Milligan et al. 2017).”
BackgroundKolb, P., Phan, K., Gao, Z., Marko, A. C., Šali, A., & Jacobson, K. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049910 · Cited by 59
“Its antagonists have been explored as kidney-protective agents, compounds for treating cardiac failure, cognitive enhancers, and antiasthmatic agents [11,12].”
BackgroundSelf-citationDeb, P. K., Deka, S., Borah, P., Abed, S. N., & Klotz, K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190716100509 · Cited by 58
Feng, W., Song, Y., Chen, C., Lu, Z., & Zhang, Y. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00558.x · Cited by 55
“regulator of tissue function, especially when energy supply acutely fails to meet cellular energy demand (Jacobson and Gao, 2006).”
BackgroundAdenosine A1but Not A2aReceptor Agonist Reduces Hyperalgesia Caused by a Surgical Incision in Rats
Zahn, P. K., Straub, H., Wenk, M., & Pogatzki-Zahn, E. M. (2007) · Anesthesiology · doi:10.1097/01.anes.0000286982.36342.3f · Cited by 53
5-Substituted 2-aminothiophenes as A1 adenosine receptor allosteric enhancers
Aurelio, L., Figler, H., Flynn, B. L., Linden, J. M., & Scammells, P. J. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.065 · Cited by 53
Hou, X., Majik, M. S., Kim, K., Pyee, Y., Lee, Y., Alexander, V. M., Chung, H., Lee, H. W., Chandra, G., Lee, J. H., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201229j · Cited by 53
Self-citationRecent improvements in the development of A2B adenosine receptor agonists
Baraldi, P. G., Tabrizi, M. A., Fruttarolo, F., Romagnoli, R., & Preti, D. (2008) · Purinergic Signalling · doi:10.1007/s11302-008-9097-z · Cited by 57
“Treatment of asthma with selective A2B AR antagonists has so far been one of the most significant therapeutic options among AR ligands [34–38].”
BackgroundSharma, A. K., LaPar, D. J., Stone, M. L., Zhao, Y., Mehta, C. K., Kron, I. L., & Laubach, V. E. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1253oc · Cited by 58
Regulation of bone and cartilage by adenosine signaling
Strazzulla, L. C., & Cronstein, B. N. (2016) · Purinergic Signalling · doi:10.1007/s11302-016-9527-2 · Cited by 60
“Extracellular adenosine concentrations vary according to physiologic and pathologic stimuli such as hypoxia and inflammation [28].”
BackgroundAdenosine kinase: A key regulator of purinergic physiology
Boison, D., & Jarvis, M. F. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114321 · Cited by 57
Mohsenin, A., Mi, T., Xia, Y., Kellems, R. E., Chen, J., & Blackburn, M. R. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00187.2007 · Cited by 57
“In contrast, genetic removal of the A3R (48), or pharmacological inhibition of the A2BR (43), revealed proinflammatory activities for these receptors in the adenosinemediated lung disease seen in ADA / mice.”
BackgroundInfluentialCyclic AMP in Rat Ileum: Evidence for the Presence of an Extracellular Cyclic AMP-Adenosine Pathway
Giron, M. C., Bin, A., Brun, P., Etteri, S., Bolego, C., Florio, C., & Gaion, R. M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.030 · Cited by 53
Wiedemann, P., Sorgente, N., Bekhor, C., Patterson, R., Tran, T., & Ryan, S. J. (1985) · PubMed · Cited by 54
Adenosine A 3 receptor activation is neuroprotective against retinal neurodegeneration
Galvão, J., Elvas, F., Martins, T., Cordeiro, M. F., Ambrósio, A. F., & Santiago, A. R. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.08.009 · Cited by 53
Caffeine treatment disturbs the angiogenesis of zebrafish embryos
Yeh, C.-H., Liao, Y.-F., Chang, C., Tsai, J., Wang, Y., Cheng, C., Wen, C., & Chen, Y. (2012) · Drug and Chemical Toxicology · doi:10.3109/01480545.2011.627864 · Cited by 52
“Drug and Chemical Toxicology uses of caffeine through interaction with the RyR and ADR receptors (Jacobson and Gao, 2006).”
BackgroundCrean, D., Cummins, E. P., Bahar, B., Mohan, H., McMorrow, J. P., & Murphy, E. P. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402039 · Cited by 52
“A2a [20 nM], A2b [140 nM], and A3 [25 nM]) (30) is maintained at 100 and 10 nM concentrations (Supplemental Fig.”
The relatively selective cyclooxygenase-2 inhibitor nimesulide: What’s going on?
Caiazzo, E., Ialenti, A., & Cicala, C. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.01.044 · Cited by 54
Binder, D. K., & Steinhäuser, C. (2016) · Elsevier eBooks · doi:10.1016/c2014-0-03100-0 · Cited by 53
Feng, Z., Sun, R., Cong, Y., & Liu, Z. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00538-3 · Cited by 52
Kurago, Z., Guo, G. F., Shi, H., Bollag, R. J., Groves, M., Byrd, J. K., & Cui, Y. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212209 · Cited by 53
“High levels of A2BR on some tumor cell types apparently promotes tumor proliferation, angiogenesis and metastasis (12, 47, 50, 51), which may be independent of immune regulation.”
BackgroundEnergy metabolism of intervertebral disc under mechanical loading
Wang, C., Gonzales, S. D., Levene, H., Gu, W., & Huang, C.-Y. C. (2013) · Journal of Orthopaedic Research® · doi:10.1002/jor.22436 · Cited by 52
Adenosine receptor antagonists alter the stability of human epileptic GABA A receptors
Roseti, C., Martinello, K., Fucile, S., Piccari, V., Mascia, A., Gennaro, G. D., Quarato, P. P., Manfredi, M., Esposito, V., Cantore, G. P., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807277105 · Cited by 55
“Because all four subtypes of ARs can couple to mitogenactivated protein kinase (MAPK) activity (13, 21), whereas activation of A3 and A2 receptors inhibit and stimulate adenylyl cyclase activity, respectively, altering PKA activity (13, 21), we speculate that the effects of AR stimulation may be associated with MAPK a…”
BackgroundRecent Developments in Adenosine A2A Receptor Ligands
Cristalli, G., Müller, C. E., & Volpini, R. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_3 · Cited by 51
Sun, K., Zhang, Y., Bogdanov, M. V., Wu, H., Song, A., Li, J., Dowhan, W., Idowu, M., Juneja, H. S., Molina, J. G., et al. (2015) · Blood · doi:10.1182/blood-2014-08-595751 · Cited by 62
“Adenosine is a potent signaling molecule that functions primarily by activating G protein–coupled receptors on target cells.(34) There are 4 adenosine receptors: ADORA1, ADORA2A, ADORA2B, and ADORA3, each with a distinct affinity for adenosine and a distinct cellular and tissue distribution.”
BackgroundBinding Kinetics of ZM241385 Derivatives at the Human Adenosine A2A Receptor
Guo, D. M., Xia, L., van Veldhoven, J. P. D., Hazeu, M., Mocking, T. A. M., Brussee, J., IJzerman, A. P., & Heitman, L. H. (2014) · ChemMedChem · doi:10.1002/cmdc.201300474 · Cited by 51
Photomodulation of G Protein-Coupled Adenosine Receptors by a Novel Light-Switchable Ligand
Bahamonde, M. I., Taura, J. J., Paoletta, S., Gakh, A. A., Chakraborty, S., Hernando, J. C., Fernández‐Dueñas, V., Jacobson, K. A., Gorostiza, P., & Ciruela, F. (2014) · Bioconjugate Chemistry · doi:10.1021/bc5003373 · Cited by 50
Self-citationThe Selective A3AR Antagonist LJ-1888 Ameliorates UUO-Induced Tubulointerstitial Fibrosis
Lee, J., Hwang, I., Lee, H., Lee, H. W., Jeong, L. S., & Ha, H. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.07.010 · Cited by 50
“Adenosine is present in normal kidneys, and its concentration increases dramatically during renal hypoxia and ischemia.(7) Extracellular adenosine signals through four known adenosine receptor (AR) subtypes, such as A1, A2A, A2B, and A3AR.”
BackgroundA DNA‐Based Plasmonic Nanodevice for Cascade Signal Amplification
Liu, F., Li, N., Shang, Y., Wang, Y., Liu, Q. L., Ma, Z., Jiang, Q., & Ding, B. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202114706 · Cited by 51
Determination of Adenosine Effects and Adenosine Receptors in Murine Corpus Cavernosum
Tostes, R. C., Giachini, F. R. C., Carneiro, F. S., Leite, R., Inscho, E. W., & Webb, R. C. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.122705 · Cited by 52
“…via adenosine receptors is thought to occur mainly through inhibition or stimulation of adenylyl cyclase, although activation of other pathways, such as phospholipase C, calcium, arachidonic acid, and mitogenactivated protein kinases, have also been described previously (Jacobson and Gao, 2006).”
BackgroundMethodInfluentialChen, H., Yang, D., Carroll, S. H., Eltzschig, H. K., & Ravid, K. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.02.001 · Cited by 50
“Louis, MO) [21] were used as antagonists for the A1, A2a, and A3 adenosine receptors, respectively [22].”
MethodModulators of Nucleoside Metabolism in the Therapy of Brain Diseases
Boison, D. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795347609 · Cited by 56
“A1Rs mediate inhibitory neuromodulation by coupling to inhibitory Gi or Go containing G proteins [12,23].”
BackgroundSitkovsky, M., & Ohta, A. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1001-9 · Cited by 49
“The importance of targeting adenosine receptors in drug development [50] was recognized by experts in drug design [25, 51] thereby providing important tools for fruitful considerations of targeting A2AR to develop anti-inflammatory drugs by Linden, Okusa, and collaborators [52].”
MethodInactivation of CD73 promotes atherogenesis in apolipoprotein E-deficient mice
Buchheiser, A., Ebner, A., Burghoff, S., Ding, Z., Romio, M., Viethen, C., Lindecke, A., Köhrer, K., Fischer, J. W., & Schrader, J. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr218 · Cited by 50
Functionalized Congener Approach to the Design of Ligands for G Protein-Coupled Receptors (GPCRs)
Jacobson, K. A. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9000596 · Cited by 51
Self-citationSárvári, M., Kalló, I., Hrabovszky, E., Solymosi, N., Tóth, K., Likó, I., Molnar, B. A., Tihanyi, K., & Liposits, Z. (2010) · Endocrinology · doi:10.1210/en.2010-0375 · Cited by 54
“Adenosine A2A receptor is a G protein-coupled receptor that mediates the role of extracellular adenosine in many physiological processes in the brain (64), including cerebral blood flow, the activity of brainstem respiratory TABLE 5.”
BackgroundKecskés, M., Kumar, T. S., Yoo, L. S., Gao, Z., & Jacobson, K. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.027 · Cited by 58
“027 the central nervous system (CNS) and in peripheral tissues, activating several G protein-dependent and independent signaling pathways [1].”
InfluentialSelf-citationA2 Adenosine Receptors and Vascular Pathologies
Johnston‐Cox, H., Koupenova, M., & Ravid, K. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.246181 · Cited by 54
“Adenosine under conditions of hypoxia stimulates the accumulation of hypoxia inducible factor-1 mediated by signaling through all AR subtypes.(115) Gessi et al demonstrated through specific pharmacological ligands that adenosine-mediated stimulation of foam cell formation was inhibited by antagonism of A3AR and A2BAR,…”
May, L. T., Self, T. J., Briddon, S. J., & Hill, S. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064493 · Cited by 153
“Allosteric binding sites on A1ARs and A3ARs represent an attractive therapeutic target for amplifying the tissue protective actions of endogenous adenosine in conditions such as ischemia, chronic neuropathic pain and inflammation (Jacobson and Gao, 2006; Cohen and Downey, 2008).”
BackgroundPoole, R. L., & Tordoff, M. G. (2017) · Journal of Caffeine Research · doi:10.1089/jcr.2016.0030 · Cited by 65
“2 Like T2Rs, ARs are GPCRs that modulate activity of effector molecules such as adenylate cyclase and PLC. 104 However, in contrast to T2Rs, which are always linked to inhibitory G proteins (i.e., G proteins that decrease levels of cAMP), AR antagonism can both increase and decrease cAMP levels depending on whether or…”
N6-methyladenosine (m6A) is an endogenous A3 adenosine receptor ligand
Ogawa, A., Nagiri, C., Shihoya, W., Inoue, A., Kawakami, K., Hiratsuka, S., Aoki, J., Ito, Y., Suzuki, T., Suzuki, T., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.038 · Cited by 51
Thein Vivoandin VitroStimulatory Effects of Cordycepin on Mouse Leydig Cell Steroidogenesis
Leu, S.-F., Poon, S. L., Pao, H.-Y., & Huang, B. (2011) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.100853 · Cited by 55
Emerging adenosine receptor agonists – an update
Gao, Z., & Jacobson, K. A. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.644786 · Cited by 49
“7 Cancer ARs are involved in cell proliferation, apoptosis, metastasis and angiogenesis, suggesting their role in cancer [1-3,9].”
BackgroundInfluentialSelf-citationBednarska, K., Olejniczak, A. B., Wojtczak, B. A., Sułowska, Z., & Lesnikowski, Z. J. (2010) · ChemMedChem · doi:10.1002/cmdc.201000075 · Cited by 48
The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis
Safarzadeh, E., Jadidi‐Niaragh, F., Motallebnezhad, M., & Yousefi, M. (2016) · Inflammation Research · doi:10.1007/s00011-016-0936-z · Cited by 54
The Impact of Purinergic System Enzymes on Noncommunicable, Neurological, and Degenerative Diseases
Bagatini, M. D., dos Santos, A. A., Cardoso, A. M., Mânica, A., Reschke, C. R., & Carvalho, F. B. (2018) · Journal of Immunology Research · doi:10.1155/2018/4892473 · Cited by 54
“Indeed, adenosine synthesis is controlled by ectonucleotidases located on the cytoplasmatic membrane, and its concentrations vary according to physiological and pathological stimuli such as hypoxia and inflammation [41, 42].”
BackgroundKalyanasundaram, A., Li, N., Hansen, B. J., Zhao, J., & Fedorov, V. V. (2018) · Journal of Veterinary Cardiology · doi:10.1016/j.jvc.2018.10.004 · Cited by 48
Varty, G. B., Hodgson, R. A., Pond, A. J., Grzelak, M. E., Parker, E. M., & Hunter, J. C. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1214-8 · Cited by 51
“Based on their pharmacology, signal transduction mechanisms, and amino acid sequence homology, the P1 class of receptors is further subdivided into four receptor subtypes: A1 ,A 2A ,A 2B, and A3 (Fredholm et al. 2001; Jacobson and Gao 2006 ).”
BackgroundChalcone-based derivatives as new scaffolds for hA3 adenosine receptor antagonists
Vázquez-Rodríguez, S., Matos, M. J., Santana, L., Uriarte, E., Borges, F., Kachler, S., & Klotz, K. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12028 · Cited by 53
Cheong, S. L., Federico, S., Venkatesan, G., Mandel, A. L., Shao, Y. M., Moro, S., Spalluto, G., & Pastorin, G. (2011) · Medicinal Research Reviews · doi:10.1002/med.20254 · Cited by 48
“human and rat A1 receptors are 89% identical across the open reading frame), A3AR of these species share only 72% identity, which determines different pharmacological profiles.(14) Owing to such species differences, some of the potent and selective derivatives for human A3AR (particularly the A3AR antagonists) have de…”
BackgroundModulation/physiology of calcium channel sub-types in neurosecretory terminals
Lemos, J. R., Ortiz-Miranda, S. I., Cuadra, A. E., Velázquez-Marrero, C., Custer, E. E., Dad, T., & Dayanithi, G. (2012) · Cell Calcium · doi:10.1016/j.ceca.2012.01.008 · Cited by 47
“There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischemic diseases, sleep disorders, immune and inflammatory disorders and cancer [98].”
BackgroundStafford, M. R., Bartlett, P. F., & Adams, D. J. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.04.013 · Cited by 55
“None the less, both receptors do activate signaling cascades downstream of these effectors and can modulate MAP kinases, such as ERK1/2 (Communi et al., 2000; Jacobson and Gao, 2006), leading to changes in cellular mitogenesis, differentiation and survival (Luttrell, 2002; Marinissen and Gutkind, 2001).”
BackgroundThe role of HIFs in ischemia-reperfusion injury
Tennant, D. A., & Howell, N. J. (2014) · Hypoxia · doi:10.2147/hp.s49720 · Cited by 53
“Conversely, A2A and B subtypes are coupled to stimulatory G proteins and result in increased cAMP levels and protein kinase A activation.(79) Both subtypes are able to activate MAPK signaling.”
Ikeda, R., Nishimura, M., Sun, Y., Wada, M., & Nakashima, K. (2008) · Biomedical Chromatography · doi:10.1002/bmc.980 · Cited by 47
A membrane network of receptors and enzymes for adenine nucleotides and nucleosides
Schicker, K. W., Hussl, S., Chandaka, G. K., Kosenburger, K., Yang, J., Waldhoer, M., Sitte, H. H., & Boehm, S. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.09.014 · Cited by 55
Insulin therapy and fetoplacental vascular function in gestational diabetes mellitus
Sobrevía, L., Salsoso, R., Sáez, T., Sanhueza, C., Pardo, F., & Leiva, A. (2015) · Experimental Physiology · doi:10.1113/expphysiol.2014.082743 · Cited by 52
“Experimental Physiology C© 2015 The Physiological Society of the A3AR also modulates phospholipase C activity via Gq or Gpt (Jacobson & Gao, 2006).”
BackgroundKim, S., Gao, Z., Jeong, L. S., & Jacobson, K. A. (2006) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2006.05.004 · Cited by 47
“Four subtypes of adenosine receptors (ARs), a rhodopsin-like Family A G-protein-coupled receptor (GPCR), have been important therapeutic targets for drug development [1].”
BackgroundResultSelf-citationNg, H. W., Laughton, C. A., & Doughty, S. W. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300610w · Cited by 47
Klein, C., Grahnert, A., Abdelrahman, A., Müller, C. E., & Hauschildt, S. (2009) · Cell Calcium · doi:10.1016/j.ceca.2009.08.004 · Cited by 50
Implications of CD39 in immune-related diseases
Zeng, J., Ning, Z., Zhang, H., Dong, G., Zhang, J., Shi, H., Yan, F., Zhao, M., Wang, C., Ma, Q., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107055 · Cited by 49
Adachi, H., Palaniappan, K. K., Ivanov, A. A., Bergman, N., Gao, Z., & Jacobson, K. A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061278q · Cited by 49
“Purity of the nucleosides submitted for biological testing was checked using a Hewlett– Packard 1100 HPLC equipped with a Luna 5μ RP-C18(2) analytical column (250 X 4.6 mm; Agilent Technologies, Santa Clara, CA).”
MethodInfluentialSelf-citationGao, Z.-G., & Jacobson, K. A. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.02.008 · Cited by 46
Self-citationGoswami, S. K., Maulik, N., & Das, D. K. (2007) · Annals of Medicine · doi:10.1080/07853890701374677 · Cited by 49
“Adenosine receptors are members of the G protein coupled receptor (GPCR) superfamily and, upon stimulation, activate pro-survival signaling kinases like ERK, p38, PKC, and Akt mediating its beneficial effects (156).”
BackgroundMaslov, I., Volkov, O., Khorn, P. A., Orekhov, P. S., Gusach, A., Kuzmichev, P. K., Gerasimov, A. S., Luginina, A. P., Coucke, Q., Bogorodskiy, A. O., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04727-z · Cited by 52
Yegutkin, G. G., Helenius, M., Kaczmarek, E., Burns, N., Jalkanen, S., Stenmark, K. R., & Gerasimovskaya, E. V. (2011) · Angiogenesis · doi:10.1007/s10456-011-9234-0 · Cited by 46
“Finally, nucleotide-derived adenosine binds to its own receptors that function either by activating (A2A and A2B) or inhibiting (A1 and A3) adenylyl cyclase [9, 17] and then either transported into the cell via specific nucleoside transporters or directly metabolized by cell-surface adenosine deaminase [10].”
BackgroundPluskal, T., & Weng, J. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00411g · Cited by 49
Caffeine and Primary (Migraine) Headaches—Friend or Foe?
Alstadhaug, K. B., & Andreou, A. P. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01275 · Cited by 57
“The roles of A2BR and A3R are not as well understood, but it appears that adenosine has a lower affinity for these receptors compared to A1R and A2AR receptors.”
BackgroundInfluentialInflammatory targets of therapy in sickle cell disease
Owusu-Ansah, A. T., Ihunnah, C. A., Walker, A. L., & Ofori-Acquah, S. F. (2015) · Translational research · doi:10.1016/j.trsl.2015.07.001 · Cited by 52
Melman, A., Gao, Z., Kumar, D., Wan, T. C., Gizewski, E. T., Auchampach, J. A., & Jacobson, K. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.001 · Cited by 45
Self-citationTosh, D. K., Yoo, L. S., Chinn, M., Hong, K., Kilbey, S. M., Barrett, M. O., Fricks, I., Harden, T. K., Gao, Z., & Jacobson, K. A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900473v · Cited by 48
“The A3AR is found at various levels of expression in neutrophils, eosinophils, cardiac myocytes, skeletal muscle, astrocytes, neurons, and other cell types (6) and has distinct effects on cell survival and response to stress.”
BackgroundMethodSelf-citationA new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines
van Veldhoven, J. P. D., Chang, L. C. W., Künzel, J. K. V. F. D., Mulder‐Krieger, T., Struensee-Link, R., Beukers, M. W., Brussee, J., & IJzerman, A. P. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.01.013 · Cited by 46
Chaudhari, D., Kuche, K., Yadav, V., Ghadi, R., Date, T., Bhargavi, N., & Jain, S. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01273-9 · Cited by 46
“The cellular uptake indicated that the ADN-modified PLGA NPs were able to internalize more effectively in TNBC cells in comparison to non-modified cells due to ADN receptor-mediated uptake [41].”
BackgroundDendrimers in Neurodegenerative Diseases
Pérez‐Carrión, M. D., & Posadas, I. (2023) · Processes · doi:10.3390/pr11020319 · Cited by 50
Nucleotides in ocular secretions: Their role in ocular physiology
Crooke, A., Guzmán‐Aránguez, A., Peral, A., Abdurrahman, M. K.-A., & Pintor, J. J. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.04.002 · Cited by 44
G‐Protein‐Coupled Receptor–Membrane Interactions Depend on the Receptor Activation State
Bhattarai, A., Wang, J., & Miao, Y. (2019) · Journal of Computational Chemistry · doi:10.1002/jcc.26082 · Cited by 44
“∆V(?⃑?) = 1 % 2 k4E − V(r)7(2), V(?⃑?) < E 0, V(?⃑?) ≥ E (1)”
BackgroundAstrocytes and Adenosine A2A Receptors: Active Players in Alzheimer’s Disease
Lopes, C. R., Cunha, R. A., & Agostinho, P. M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666710 · Cited by 52
De Novo Molecule Design Using Molecular Generative Models Constrained by Ligand–Protein Interactions
Zhang, J., & Chen, H. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00177 · Cited by 53
G Protein‐Coupled Receptors and Adipogenesis: A Focus on Adenosine Receptors
Eisenstein, A. S., & Ravid, K. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24473 · Cited by 48
“J o u r n a l o fl Cellular Physiology 2 0 1 3 W I L E Y P E R I O D I C A L S , I N C . adipocytes to differentiate (Danforth, 2000; Jansson et al., 2003; Spalding et al., 2008).”
BackgroundEscudero, C., Bertoglia, P., Hernadez, M., Celis, C., González, M., Aguayo, C. R., & Acurio, J. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9341-4 · Cited by 42
“Adenosine is an endogenous purinergic nucleoside involved in angiogenesis via the activation of adenosine receptors (ARs) in both normal and pathological conditions (see [18]), which may include the human placenta in preeclampsia [6, 16, 19].”
Zhao, P., Li, X., Yang, M., Shao, Q., Wang, D., Liu, S., Song, H., Song, B., Zhang, Y., & Qu, X. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2007.12.002 · Cited by 48
Toward Multivalent Signaling across G Protein-Coupled Receptors from Poly(amidoamine) Dendrimers
Kim, Y., Hechler, B., Klutz, A. M., Gachet, C., & Jacobson, K. A. (2008) · Bioconjugate Chemistry · doi:10.1021/bc700327u · Cited by 46
Self-citationBarrier Enhancing Signals in Pulmonary Edema
Birukov, K. G., Zebda, N., & Birukova, A. A. (2012) · Comprehensive physiology · doi:10.1002/cphy.c100066 · Cited by 46
Deb, P. K., Balakumar, C., Akkinepally, R. R., Roy, P. P., & Roy, K. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.094 · Cited by 43
Therapeutic Opportunities in Damage-Associated Molecular Pattern-Driven Metabolic Diseases
Garcia-Martinez, I., Shaker, M. E., & Mehal, W. Z. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6383 · Cited by 43
“Adenosine biology is well suited to regulate inflammasome activity because extracellular adenosine concentrations are elevated in response to tissue damage, and adenosine is also rapidly removed from tissues by adenosine deaminase-mediated metabolism (38, 74).”
BackgroundNeedling adenosine receptors for pain relief
Zylka, M. J. (2010) · Nature Neuroscience · doi:10.1038/nn0710-783 · Cited by 43
Wong, R., & Schlichter, L. C. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2014.11.711 · Cited by 43
do Nascimento, F. P., Macedo-Júnior, S. J., Pamplona, F. A., Cerutti, M. L., Córdova, M. M., Constantino, L. C., Tasca, C. I., Dutra, R. C., Calixto, J. Β., Reid, A. R., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8815-5 · Cited by 50
“When activated, this G protein-coupled receptor inhibits adenylyl cyclase, opens potassium channels and blocks calcium channels; additionally, A1R activation through phospholipase C can increase both intracellular calcium and inositol triphosphate [4, 6, 7].”
BackgroundKim, J., Karpyak, V. M., Biernacka, J. M., Nam, H. W., Lee, M. R., Preuss, U. W., Zill, P., Yoon, G., Colby, C. L., Mrazek, D. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016331 · Cited by 46
“Several preclinical and clinical trials have suggested that the regulation of adenosine levels might be effective in treating epileptic seizures [13,14,15].”
BackgroundSeibt, B. F., Schiedel, A. C., Thimm, D., Hinz, S., Sherbiny, F. F., & Müller, C. E. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.005 · Cited by 44
Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist
Anderson, S. D., Shah, N. K., Yim, J., & Epstein, B. J. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m548 · Cited by 43
Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor
Baltos, J., Paoletta, S., Nguyen, A. T. N., Gregory, K. J., Tosh, D. K., Christopoulos, A., Jacobson, K. A., & May, L. T. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.103283 · Cited by 45
Self-citationVarani, K., Vincenzi, F., Merighi, S., Gessi, S., & Borea, P. A. (2017) · Advances in experimental medicine and biology · doi:10.1007/5584_2017_61 · Cited by 47
Wong, R., & Schlichter, L. C. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1008-14.2014 · Cited by 47
Slee, D. H., Chen, Y., Zhang, X., Moorjani, M., Lanier, M. C., Lin, E., Rueter, J. K., Williams, J. P., Lechner, S. M., Markison, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701185v · Cited by 51
Adenosine A2areceptors and O2sensing in development
Koos, B. J. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00664.2010 · Cited by 49
“A2A receptor signaling also can occur independently of G proteins (93, 146, 382).”
Background
Metadata
- Authors
- Jacobson, K. A., & Gao, Z.-G.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Jacobson, Kenneth A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 247-264
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3463109
- OpenAlex
- W1985598247
- Cited by
- 1,431
- References
- 215
- Citations by year
- 2026: 34 · 2025: 50 · 2024: 52 · 2023: 55 · 2022: 80 · 2021: 58 · 2020: 65 · 2019: 79 · 2018: 66 · 2017: 59 · 2016: 65 · 2015: 64 · 2014: 80 · 2013: 80 · 2012: 83
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (Z01DK031117)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- adenosine receptors, adenosine receptor agonists, adenosine receptor antagonists, selective ligands, caffeine, cardiovascular disease, ischemic diseases, sleep disorders, inflammatory diseases, cancer, neurological disorders, drug development
- MeSH terms
- Animals, Disease, Drug Therapy, Humans, Ligands, Structure-Activity Relationship, Molecular Structure, Signal Transduction, Receptors, Purinergic P1, Purinergic P1 Receptor Agonists, Purinergic P1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.